Presentations
|
|
|
|
S Munster P, Krischer J, Tamura R, Fink A, et al.
|
|
|
The authors conclude that: In patients with HER2-positive breast cancer receiving trastuzumab and an anthracycline, both lisino-pril and carvedi-lol during treatment reduced cardiotoxicity in patients, but not in those with non-anthracyline containing regimens. The use of lisino-pril or carvedi-lol may allow the use of an anthracycline without compromising trastuzumab treatment in those who might benefit from an anthracycline.
|
|
|
[GS5-02] Cardiovascular function and the effect of exercise training during adjuvant breast cancer treatment. Results from The EBBA-II trial |
|
|
Thune I, Husøy A, Frydenberg H, Flote VG, et al.
|
|
|
The authors conclude that: Our findings strongly support that tailored exercise training during adjuvant breast cancer treatment may counteract a decline in cardiovascular function, and in particular among those receiving chemotherapy. Our study supports incorporation of supervised clinical exercise programs into breast cancer treatment guidelines.
|
|
|
|
|
|
Janni W, Rack BK, Friedl TW, Müller V, et al.
|
|
|
The authors conclude that: This explorative and non-planned interim analysis indicates that the completion of a systematic telephone life style intervention program may positively impact patient outcome in early breast cancer.
|
|
|
|
|
|
||
|
[GS5-05] Resistance to neoadjuvant chemotherapy in triple negative breast cancer mediated by a reversible drug-tolerant state |
|
|
Echeverria GV, Ge Z, Seth S, Jeter-Jones SL, et al.
|
|
|
The authors conclude that: Collectively, these studies reveal that a reversible phenotypic state can confer chemoresistance in the absence of genomic selection and that the residual tumor state is a novel therapeutic window for chemo-refractory TNBC.
|
|
|
[GS5-06] No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial |
|
|
Gluz O, Nitz U, Liedtke C, Prat A, et al.
|
|
|
The authors conclude that: Our exploratory results suggest independent prognostic impact of mRNA markers and TIL's in early TNBC. Patients with both pCR (after 12 weeks) and “high-immune” signature (defined here by PD1) had excellent 3y-EFS and may be candidates for treatment de-escalation (e.g. omission of anthracyclines), whereas “low-immune” pCR patients may benefit from standard adjuvant poly-chemotherapy.
|
|
|
Hartkopf AD, Brucker SY, Taran F-A, Harbeck N, et al.
The authors conclude that: Detection of DTC in the bone marrow is an independent prognostic marker in patients with non-metastatic breast cancer. Further studies should investigate the impact of DTC on metastatic cancer progression and their role for clinical decision making. |
|
San Antonio - Mosaic on a pillar of streetcar station